DE ACORDO com o texto,

Texto-base para as questões 05, 06, e 07 . Once essential, CoronaVac is at risk of being left out of Brazil’s immunization program Vaccine i...

Texto-base para as questões 05, 06, e 07.

Once essential, CoronaVac is at risk of being left out of

Brazil’s immunization program

Vaccine is less effective against coronavirus variants

A pioneer in the fight against Covid in Brazil, the CoronaVac vaccine may have its days numbered in the country.

The vaccine developed by the Chinese laboratory Sinovac and produced here by the Butantan Institute, played an essential role in the beginning of vaccination against the coronavirus, representing 85% of the doses applied in March 2021.

Gradually, it lost ground to other brands and ended last year accounting for less than 10% of applications in the country.

And that rate could decrease even further.

This is because on Monday (18) the Minister of Health, Marcelo Queiroga, announced that the use of the immunizing agent will be restricted to children and adolescents aged 5 to 18 years, withdrawing the vaccine from the National Immunization Program for adults.

In addition, studies show that the effectiveness of CoronaVac as a booster dose against new variants tends to be lower than that of other manufacturers.

Thus, its use in new vaccination campaigns has been ruled out by the federal government.

Source: https://www1.folha.uol.com.br/internacional/en/science-andhealth/2022/04/once-essential-coronavac-is-at-risk-of-being-left-out-of-brazils-immunization-program.shtml

UNIOESTE 2022 - QUESTÃO 06

DE ACORDO com o texto,

a) a vacina, desenvolvida pelo Instituto Butantan e fabricada pelo laboratório Sinovac, representou 85% das doses aplicadas no Brasil em março de 2021.

b) a vacina, desenvolvida pelo laboratório chinês Sinovac e fabricada pelo Instituto Butantan, representou 85% das doses aplicadas no Brasil em março de 2021.

c) a vacina, desenvolvida pelo laboratório Sinovac e fabricada pelo Instituto Butantan, teve eficácia de 85% no Brasil.

d) a vacina desenvolvida pelo Butantan teve eficácia de pelo menos 15% no Brasil.

e) 15% das vacinas desenvolvidas pelo Butantan foram eficazes no combate à Covid no Brasil.

QUESTÃO ANTERIOR:

- DE ACORDO com o texto, a vacina CoronaVac

GABARITO:

b) a vacina, desenvolvida pelo laboratório chinês Sinovac e fabricada pelo Instituto Butantan, representou 85% das doses aplicadas no Brasil em março de 2021.

RESOLUÇÃO:

Não temos resolução para essa questão! Você sabe explicar? Copie o link dessa página e envie sua resolução clicando AQUI!

PRÓXIMA QUESTÃO:

- Ainda DE ACORDO com o texto,

QUESTÃO DISPONÍVEL EM:

- Prova Unioeste 2022 (Manhã e Tarde) com Gabarito